Key terms

About ANVS

Annovis Bio, Inc. is a clinical stage drug platform company, which engages in the development of drugs which aim to treat neurodegenerative diseases such as Alzheimer's (AD) and Parkinson's (PD). Its lead product candidate, Buntanetap, is designed to address AD, PD, and potentially other chronic neurodegenerative diseases. Its product pipeline also includes ANVS405 and ANVS301, which focus on the treatment of traumatic brain injury, stroke, and advanced AD. The company was founded by Maria Luisa Maccecchini in May 2008 and is headquartered in Malvern, PA.

Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
     
52-week range
     
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date

Key terms

Smart score

Latest ANVS news

Apr 16 12:00pm ET Annovis Bio falls -9.6% by TipRanks Apr 15 8:46am ET Largest borrow rate increases among liquid names by TipRanks Apr 12 8:46am ET Largest borrow rate increases among liquid names by TipRanks Apr 04 8:46am ET Largest borrow rate increases among liquid names by TipRanks Apr 03 8:46am ET Largest borrow rate increases among liquid names by TipRanks Apr 02 8:46am ET Largest borrow rate increases among liquid names by TipRanks Apr 02 6:25am ET Buy Rating Reiterated for Annovis Bio Amid Anticipated Positive Trial Results for Alzheimer’s and Parkinson’s Treatments by TipRanks Apr 01 8:16am ET Annovis Bio announces publication on buntanetap by TipRanks Mar 25 8:46am ET Largest borrow rate increases among liquid names by TipRanks Mar 22 10:00am ET Annovis Bio falls -9.0% by TipRanks Mar 21 3:10pm ET Analysts Are Bullish on Top Healthcare Stocks: Annovis Bio (ANVS), AbSci (ABSI) by TipRanks Mar 21 7:40am ET Analysts Are Bullish on These Healthcare Stocks: Insulet (PODD), Annovis Bio (ANVS) by TipRanks Mar 21 6:31am ET Analysts Are Bullish on Top Healthcare Stocks: Femasys (FEMY), BioNTech SE (BNTX) by TipRanks Mar 20 4:52pm ET Annovis Bio Promises Market-Impacting Information Release by TipRanks Mar 20 12:00pm ET Annovis Bio rises 30.0% by TipRanks Mar 20 9:47am ET Annovis Bio rises 8.7% by TipRanks Mar 20 7:33am ET Annovis Bio completes data cleaning for Phase II/III study of buntanetap by TipRanks Mar 18 10:00am ET Annovis Bio rises 9.1% by TipRanks Feb 28 4:58am ET Annovis Bio downgraded to Hold from Buy at Brookline by TipRanks Feb 28 4:55am ET Maintaining Hold on Annovis Bio Amid Phase 3 Parkinson’s Trial Concerns and Financial Uncertainties by TipRanks Feb 27 8:45am ET Largest borrow rate increases among liquid names by TipRanks Feb 26 12:00pm ET Annovis Bio falls -12.0% by TipRanks Feb 20 8:45am ET Largest borrow rate increases among liquid names by TipRanks Feb 16 8:45am ET Largest borrow rate increases among liquid names by TipRanks Feb 15 1:35pm ET Buy Rating Justified for Annovis Bio Amidst Promising Buntanetap Clinical Trials and Strong Commercial Prospects by TipRanks Feb 15 1:30pm ET Analysts Are Bullish on These Healthcare Stocks: Annovis Bio (ANVS), Alnylam Pharma (ALNY) by TipRanks Feb 15 6:25am ET Buy Rating on Annovis Bio Amid Anticipated Positive Outcomes for Buntanetap in AD and PD Trials by TipRanks Feb 14 7:35am ET Annovis announces last patient last visit in Phase II/III study of buntanetap by TipRanks Feb 12 8:45am ET Largest borrow rate increases among liquid names by TipRanks Feb 08 8:45am ET Largest borrow rate increases among liquid names by TipRanks Feb 02 12:00pm ET Annovis Bio falls -9.6% by TipRanks
May 04 4:30am ET Annovis Bio Announces First Quarter 2022 Results and Provides Corporate Update by NewsFile Apr 28 12:30pm ET Annovis Bio Announces Cooperative Research and Development Agreement (CRADA) with the National Institute on Aging by NewsFile Apr 11 4:30am ET Annovis Bio to Participate in World Parkinson's Day to Raise Awareness on the Debilitating Disease by NewsFile Mar 23 4:30am ET Annovis Bio to Present at the 2022 Virtual Growth Conference Presented by Maxim Group LLC and Hosted by M-Vest by NewsFile Mar 18 4:30am ET Annovis Bio Presents at International Conference on Alzheimer's & Parkinson (AD/PD 2022) by NewsFile Mar 08 3:30am ET Annovis Bio Announces Presentation at International Conference on Alzheimer's & Parkinson's Diseases 2022 by NewsFile Mar 03 3:30am ET Annovis Bio to Present at the Cowen 42nd Annual Health Care Conference by NewsFile Jan 25 4:00am ET Annovis Bio Announces Positive FDA Feedback for Buntanetap Phase 3 Clinical Development in Parkinson's Disease by NewsFile Jan 10 3:30am ET Annovis Bio Enhances Leadership Team with Two Senior Appointments by NewsFile Jan 05 3:30am ET Annovis Bio Announces Official Unique Name Buntanetap for Lead Candidate ANVS401 by NewsFile Jan 03 3:30am ET Annovis Bio to Participate in the Biotech Showcase and H.C. Wainwright Bioconnect Virtual Conferences by NewsFile

ANVS Financials

1-year income & revenue

Key terms

ANVS Forecasts

analyst rating

  • buy
  • hold
  • sell

We're sorry, but this
information is
temporarily unavailable.

1-year stock price forecast

ANVS Competitors

$ Market cap P/E ratio $ Price 1d change 52-week range

Key terms

Latest investing news

Trump Media, which runs the social media platform Truth Social, took the place of Digital World's place on the Nasdaq stock exchange in March.
Frank Franklin II/AP
Trump Media stock ends session 15% higher after two very bad days
Students at Highlands High School, work on a practice test at the ACT Boot Camp in Newport, Ky.
Patrick Reddy/The Enquirer/AP/File
Private equity finds its next bet: college admissions
In this photo illustration, Republican presidential candidate former President Donald Trump's social media platform Truth Social is shown on a cell phone on March 25, 2024 in Chicago, Illinois.
Scott Olson/Getty Images
Trump’s stock tumbles again after Truth Social announces it’s getting into streaming
Tim Wren, chief commercial officer for BSI Group, right, presents Kristalina Georgieva, chief executive officer of the World Bank Group, second right, with ISO 20121 certification for sustainable event management at an event during the spring meetings of the International Monetary Fund (IMF) and World Bank in Washington, DC, US, on Monday, April 15, 2024. The IMF and World Bank spring meetings in Washington are expected to draw thousands of delegates, observers and journalists from the fund's 190 member countries. Photographer: Samuel Corum/Bloomberg via Getty Images
Samuel Corum/Bloomberg/Getty Images
Geopolitical strife is roiling Wall Street. Here’s what investors are watching